Opinion|Videos|December 12, 2025
Ongoing Research to Watch at ASH 2025 and Beyond
Author(s)Jonathan Webster, MD, Nikesh Shah, MD
Jonathan Webster, MD, and Nikesh Shah, MD, discuss ALL data and research to look out for at ASH 2025.
Advertisement
Episodes in this series
Jonathan Webster, MD, and Nikesh Shah, MD, highlight key ALL data anticipated at the 2025 ASH Annual Meeting, including updates from pivotal immunotherapy studies and trials exploring targeted agents. They discuss how these findings may refine treatment selection, deepen understanding of MRD-guided care, and influence long-term management strategies. They also identify emerging areas of scientific interest that may define the next wave of innovation in ALL research.
Advertisement
Related to this article
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Long-term follow-up showed pTVG-HP nearly doubled median OS compared with placebo in biochemically recurrent prostate cancer.
The FDA has granted fast track designation for safusidenib in IDH1-mutant glioma, with a phase 3 trial on the way.
Dana-Farber research aided in the FDA approval of iberdomide-based therapy in relapsed/refractory multiple myeloma.
Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.
The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC
4
Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer
5